DUBLIN, Ireland--(BUSINESS WIRE)--March 8, 2004--Responding to a number of recent inquiries from the investment community, Elan Corporation, plc today reiterated the terms of its Series Z warrants. As reported in Elan's Annual Report on Form 20-F for the fiscal year ended December 31, 2002, each Series Z warrant is exercisable into 0.127585 of an Elan American Depositary Share (ADS). Each ADS represents one Elan Ordinary Share, at an exercise price of $26.72 per ADS, subject to certain anti-dilution adjustments. The Series Z warrants expire at 5:00 p.m. Eastern Time on August 31, 2005.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain. Elan (NYSE: ELN) shares trade on the New York, London and Dublin Stock Exchanges.
CONTACT: Investors:
Emer Reynolds, 353-1-709-4000
800-252-3526
or:
Media:
Anita Kawatra, 212-407-5755
800-252-3526
SOURCE: Elan Corporation, plc
Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use